The images below are from the last amendment to our last NASDAQ prospectus.
https://www.sec.gov/Archives/edgar/data/1760764/000121390019009923/ff12019a1_gmedical.htm#a_009
If we use similar ratios we will be looking at 1,050,000,000 shares on issue. 210,000,000 offered during IPO.
Obviously this is without consolidation.
On the previous prospectus the consolidation was approximately 70:1. That would mean there are 15,000,000 ADS shares on issue to current share holders (ASX) + 3,000,000 ADS offered at IPO.
The last IPO price was $10.50 USD per ADS. If this was achieved (I have no doubt, I expect much higher tbh) it would give us a MC of $189,000,000. That is a significant re-rate. However only a PE of 8x if we use the forward looking $25m pa revenue.
That alone would be a 500% increase roughly on last closing price.
I am expecting a similar prospectus. Someone feel free to check my maths and figures. I have listed the shares on issue at 1,050,000,000 as that would have ASX equity at 80% and NASDAQ at 20% which is the same as the last offering. I have then consolidated at 70:1 as that was the consolidation considered last time as seen in the photos (highlighted). Offering price is also highlighted.
Expand
